20S Proteasome β3 Activators

20S Proteasome β3 Activators encompass a class of compounds that specifically act to increase the activity of the β3 subunit within the 20S proteasome-a core component of the ubiquitin-proteasome system responsible for non-lysosomal protein degradation. This complex is a cylindrical structure composed of four stacked rings, each containing multiple protein subunits; the β3 subunit resides within the inner rings and is integral to the proteasome's proteolytic function. Activators targeting the β3 subunit can enhance its native catalytic activity, thereby upregulating the proteasome's overall capacity to process and degrade polypeptides into short peptides.

The activation of the 20S Proteasome β3 subunit can occur through different biochemical mechanisms. For instance, small molecules like Bortezomib are known to bind reversibly to the proteasome and initially act as inhibitors. However, this interaction can lead to a paradoxical upregulation of proteasomal activity upon brief exposure, a phenomenon possibly due to the cell's compensatory response to the transient inhibition. This response can result in an increase in the functional capacity of the β3 subunit. Other proteasome inhibitors, such as Carfilzomib, which binds irreversibly, and Ixazomib, can also induce a similar compensatory upregulation of proteasome subunits, including β3, following proteasome inhibition. Furthermore, agents like Epoxomicin, which forms a stable, irreversible complex with the proteasome, can also trigger an increase in the expression of proteasome subunits. This effect indicates that cells can respond to the altered functional state of the proteasome by enhancing the activity of the remaining active sites, such as those on the β3 subunit.